Aytu Biopharma annual revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Aytu Biopharma Revenue Growth & History (AYTU)
Aytu Biopharma reported $66.4M in revenue for fiscal 2025, an increase of 1.84% from the previous fiscal year.
View full Aytu Biopharma company overviewAytu Biopharma annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $66.4M | $1.2M | +1.84% |
| 2024 | 2024-06-30 | $65.2M | −$42.2M | −39.31% |
| 2023 | 2023-06-30 | $107.4M | $10.7M | +11.10% |
| 2022 | 2022-06-30 | $96.7M | $31.0M | +47.29% |
| 2021 | 2021-06-30 | $65.6M | $38.0M | +137.52% |
| 2020 | 2020-06-30 | $27.6M | $20.3M | +277.49% |
| 2019 | 2019-06-30 | $7.3M | $3.7M | +100.00% |
| 2018 | 2018-06-30 | $3.7M | $438,410 | +13.61% |
| 2017 | 2017-06-30 | $3.2M | $659,145 | +25.72% |
| 2016 | 2016-06-30 | $2.6M | $2.3M | +878.85% |
| 2015 | 2015-06-30 | $261,782 | $202,853 | +344.23% |
| 2014 | 2014-06-30 | $58,929 | — | — |
| 2013 | 2013-08-31 | $1,750 | $0 | 0.00% |
| 2012 | 2012-08-31 | $1,750 | — | — |
Aytu Biopharma quarterly revenue
Q1.11
Q1.12
Q3.13
Q2.14
Q3.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q3 2026 | 2026-03-31 | $12.4M | −$6.0M | −32.74% |
| Q2 2026 | 2025-12-31 | $15.2M | −$1.1M | −6.51% |
| Q1 2026 | 2025-09-30 | $13.9M | −$2.7M | −16.21% |
| Q4 2025 | 2025-06-30 | $15.1M | $542,000 | +3.71% |
| Q3 2025 | 2025-03-31 | $18.5M | $4.4M | +31.57% |
| Q2 2025 | 2024-12-31 | $16.2M | −$2.5M | −13.48% |
| Q1 2025 | 2024-09-30 | $16.6M | −$1.2M | −6.98% |
| Q4 2024 | 2024-06-30 | $14.6M | −$16.1M | −52.52% |
| Q3 2024 | 2024-03-31 | $14.0M | −$8.7M | −38.31% |
| Q2 2024 | 2023-12-31 | $18.7M | −$7.5M | −28.66% |
| Q1 2024 | 2023-09-30 | $17.8M | −$9.8M | −35.57% |
| Q4 2023 | 2023-06-30 | $30.7M | $3.3M | +11.96% |
| Q3 2023 | 2023-03-31 | $22.7M | −$1.5M | −6.06% |
| Q2 2023 | 2022-12-31 | $26.3M | $3.2M | +13.64% |
| Q1 2023 | 2022-09-30 | $27.7M | $5.8M | +26.30% |
| Q4 2022 | 2022-06-30 | $27.4M | $4.0M | +16.89% |
| Q3 2022 | 2022-03-31 | $24.2M | $10.7M | +79.48% |
| Q2 2022 | 2021-12-31 | $23.1M | $8.0M | +52.67% |
| Q1 2022 | 2021-09-30 | $21.9M | $8.4M | +61.96% |
| Q4 2021 | 2021-06-30 | $23.5M | $8.6M | +58.02% |
| Q3 2021 | 2021-03-31 | $13.5M | $5.3M | +65.31% |
| Q2 2021 | 2020-12-31 | $15.1M | $12.0M | +377.04% |
| Q1 2021 | 2020-09-30 | $13.5M | $12.1M | +838.89% |
| Q4 2020 | 2020-06-30 | $14.9M | $13.1M | +763.49% |
| Q3 2020 | 2020-03-31 | $8.2M | $5.8M | +243.85% |
| Q2 2020 | 2019-12-31 | $3.2M | $1.4M | +76.89% |
| Q1 2020 | 2019-09-30 | $1.4M | $8,000 | +0.56% |
| Q4 2019 | 2019-06-30 | $1.7M | $795,522 | +85.96% |
| Q3 2019 | 2019-03-31 | $2.4M | $1.8M | +290.77% |
| Q2 2019 | 2018-12-31 | $1.8M | $743,846 | +70.76% |
| Q1 2019 | 2018-09-30 | $1.4M | $355,632 | +33.04% |
| Q4 2018 | 2018-06-30 | $925,478 | $89,588 | +10.72% |
| Q3 2018 | 2018-03-31 | $607,000 | −$286,548 | −32.07% |
| Q2 2018 | 2017-12-31 | $1.1M | $256,982 | +32.36% |
| Q1 2018 | 2017-09-30 | $1.1M | $378,388 | +54.21% |
| Q4 2017 | 2017-06-30 | $835,890 | −$101,415 | −10.82% |
| Q3 2017 | 2017-03-31 | $893,548 | $225,007 | +33.66% |
| Q2 2017 | 2016-12-31 | $794,172 | $324,958 | +69.26% |
| Q1 2017 | 2016-09-30 | $697,980 | $210,595 | +43.21% |
| Q4 2016 | 2016-06-30 | $937,305 | — | — |
| Q3 2016 | 2016-03-31 | $668,541 | $644,712 | +2705.58% |
| Q2 2016 | 2015-12-31 | $469,214 | $440,879 | +1555.95% |
| Q1 2016 | 2015-09-30 | $487,385 | $459,802 | +1666.98% |
| Q3 2015 · Mar 31 | 2015-03-31 | $23,829 | $11,329 | +90.63% |
| Q2 2015 · Dec 31 | 2014-12-31 | $28,335 | — | — |
| Q1 2015 | 2014-09-30 | $27,583 | — | — |
| Q3 2014 | 2014-05-31 | $1,000 | −$750 | −42.86% |
| Q2 2014 · Mar 31 | 2014-03-31 | $12,500 | — | — |
| Q3 2013 | 2013-05-31 | $1,750 | — | — |
| Q1 2012 | 2011-11-30 | $0 | $0 | — |
| Q1 2011 | 2010-11-30 | $0 | — | — |
Aytu Biopharma revenue growth trends
Over the last five reported fiscal years, revenue grew from $27.6M to $66.4M, a compound annual growth rate of 19.16%. Aytu Biopharma's latest reported quarter, Q3 2026, generated $12.4M in revenue, a decrease of 32.74% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Aytu Biopharma source filings ↗